vs

Side-by-side financial comparison of Doximity, Inc. (DOCS) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $185.1M, roughly 1.2× Doximity, Inc.). Doximity, Inc. runs the higher net margin — 33.3% vs 19.4%, a 13.9% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 9.8%). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 25.2%).

Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

DOCS vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.2× larger
ORGO
$225.6M
$185.1M
DOCS
Growing faster (revenue YoY)
ORGO
ORGO
+68.4% gap
ORGO
78.1%
9.8%
DOCS
Higher net margin
DOCS
DOCS
13.9% more per $
DOCS
33.3%
19.4%
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
25.2%
DOCS

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
DOCS
DOCS
ORGO
ORGO
Revenue
$185.1M
$225.6M
Net Profit
$61.6M
$43.7M
Gross Margin
89.9%
Operating Margin
38.9%
28.1%
Net Margin
33.3%
19.4%
Revenue YoY
9.8%
78.1%
Net Profit YoY
-18.1%
469.5%
EPS (diluted)
$0.31
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DOCS
DOCS
ORGO
ORGO
Q4 25
$185.1M
$225.6M
Q3 25
$168.5M
$150.9M
Q2 25
$145.9M
$101.0M
Q1 25
$138.3M
$86.7M
Q4 24
$168.6M
$126.7M
Q3 24
$136.8M
$115.2M
Q2 24
$126.7M
$130.2M
Q1 24
$118.1M
$110.0M
Net Profit
DOCS
DOCS
ORGO
ORGO
Q4 25
$61.6M
$43.7M
Q3 25
$62.1M
$21.6M
Q2 25
$53.3M
$-9.4M
Q1 25
$62.5M
$-18.8M
Q4 24
$75.2M
$7.7M
Q3 24
$44.2M
$12.3M
Q2 24
$41.4M
$-17.0M
Q1 24
$40.6M
$-2.1M
Gross Margin
DOCS
DOCS
ORGO
ORGO
Q4 25
89.9%
Q3 25
90.3%
Q2 25
89.2%
Q1 25
89.5%
72.6%
Q4 24
91.6%
75.5%
Q3 24
90.0%
76.7%
Q2 24
89.3%
77.6%
Q1 24
89.4%
73.9%
Operating Margin
DOCS
DOCS
ORGO
ORGO
Q4 25
38.9%
28.1%
Q3 25
37.8%
13.7%
Q2 25
37.4%
-12.5%
Q1 25
35.2%
-30.9%
Q4 24
47.4%
8.1%
Q3 24
38.8%
5.4%
Q2 24
36.4%
-10.7%
Q1 24
35.5%
-3.5%
Net Margin
DOCS
DOCS
ORGO
ORGO
Q4 25
33.3%
19.4%
Q3 25
36.8%
14.3%
Q2 25
36.5%
-9.3%
Q1 25
45.2%
-21.7%
Q4 24
44.6%
6.1%
Q3 24
32.3%
10.7%
Q2 24
32.7%
-13.1%
Q1 24
34.4%
-1.9%
EPS (diluted)
DOCS
DOCS
ORGO
ORGO
Q4 25
$0.31
$0.31
Q3 25
$0.31
$0.11
Q2 25
$0.27
$-0.10
Q1 25
$0.31
$-0.17
Q4 24
$0.37
$0.05
Q3 24
$0.22
$0.09
Q2 24
$0.21
$-0.13
Q1 24
$0.20
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DOCS
DOCS
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$64.8M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$979.3M
$300.1M
Total Assets
$1.2B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DOCS
DOCS
ORGO
ORGO
Q4 25
$64.8M
$93.7M
Q3 25
$169.2M
$63.7M
Q2 25
$137.3M
$73.1M
Q1 25
$209.6M
$110.0M
Q4 24
$165.3M
$135.6M
Q3 24
$184.2M
$94.3M
Q2 24
$111.4M
$89.9M
Q1 24
$96.8M
$88.6M
Total Debt
DOCS
DOCS
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
DOCS
DOCS
ORGO
ORGO
Q4 25
$979.3M
$300.1M
Q3 25
$1.1B
$255.1M
Q2 25
$1.0B
$233.2M
Q1 25
$1.1B
$242.9M
Q4 24
$1.0B
$262.9M
Q3 24
$961.2M
$278.5M
Q2 24
$913.6M
$263.5M
Q1 24
$901.4M
$278.0M
Total Assets
DOCS
DOCS
ORGO
ORGO
Q4 25
$1.2B
$598.7M
Q3 25
$1.3B
$509.8M
Q2 25
$1.2B
$461.1M
Q1 25
$1.3B
$467.4M
Q4 24
$1.2B
$497.9M
Q3 24
$1.1B
$446.3M
Q2 24
$1.1B
$443.2M
Q1 24
$1.1B
$458.5M
Debt / Equity
DOCS
DOCS
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DOCS
DOCS
ORGO
ORGO
Operating Cash FlowLast quarter
$60.9M
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.99×
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DOCS
DOCS
ORGO
ORGO
Q4 25
$60.9M
$39.4M
Q3 25
$93.9M
$3.1M
Q2 25
$62.1M
$-32.9M
Q1 25
$98.5M
$-19.9M
Q4 24
$65.2M
$10.9M
Q3 24
$68.3M
$8.7M
Q2 24
$41.2M
$4.7M
Q1 24
$63.9M
$-10.2M
Free Cash Flow
DOCS
DOCS
ORGO
ORGO
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
Q1 24
$-12.4M
FCF Margin
DOCS
DOCS
ORGO
ORGO
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Q1 24
-11.3%
Capex Intensity
DOCS
DOCS
ORGO
ORGO
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
0.0%
4.2%
Q4 24
0.0%
2.7%
Q3 24
0.0%
2.2%
Q2 24
0.0%
1.4%
Q1 24
0.0%
2.0%
Cash Conversion
DOCS
DOCS
ORGO
ORGO
Q4 25
0.99×
0.90×
Q3 25
1.51×
0.14×
Q2 25
1.16×
Q1 25
1.58×
Q4 24
0.87×
1.43×
Q3 24
1.55×
0.71×
Q2 24
1.00×
Q1 24
1.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DOCS
DOCS

Subscription$175.4M95%
Service Other$9.7M5%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons